RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM
The aim of this study was to assess the risk of use of rivaroxaban, which was associated with gastro-duodenal bleeding in patients with deep venous thrombosis. Methods: an analysis of anticoagulant treatment in 683 patients with deep venous phlebothrombosis. All the patients underwent fiberoptic gas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2019-06-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/181 |
| _version_ | 1797883927653777408 |
|---|---|
| author | E. A. Shcheglov N. N. Alontseva P. S. Guliaeva |
| author_facet | E. A. Shcheglov N. N. Alontseva P. S. Guliaeva |
| author_sort | E. A. Shcheglov |
| collection | DOAJ |
| description | The aim of this study was to assess the risk of use of rivaroxaban, which was associated with gastro-duodenal bleeding in patients with deep venous thrombosis. Methods: an analysis of anticoagulant treatment in 683 patients with deep venous phlebothrombosis. All the patients underwent fiberoptic gastroduodenoscopic procedure prior to the anticoagulant treatment. When erosive-ulcerative lesions were detected, the patients received antisecretory therapy with proton pump inhibitors along with anticoagulant therapy. Results: EGD did not show any only stomach pathology only in 10.7 percent of patients at the time of admission. A symptom-free pathology that became a diagnostic finding was identified in 53.1 percent of patients. Fiberoptic gastroduodenoscopy showed completed bleeding or bleeding that was stopped using endoscopic balloon tamponade with achievement of stable hemostasis in 12.9 patients. 59.1 percent of patients received anti-coagulant therapy with rivaroxaban (Xarelto®). In the presented series of patients with acute deep vein thrombosis, the use of rivopoxaban appeared a safe therapeutic option not only in patients with erosive-ulcerative lesions in the gastroduodenal system, but also in those with endoscopic signs of stopped bleeding (on the top of already administered antisecretory therapy with proton pump inhibitors). |
| first_indexed | 2024-04-10T03:59:37Z |
| format | Article |
| id | doaj.art-8a5c171b2665427d91b01e473d54f382 |
| institution | Directory Open Access Journal |
| issn | 2307-1109 2658-5952 |
| language | Russian |
| last_indexed | 2024-04-10T03:59:37Z |
| publishDate | 2019-06-01 |
| publisher | «REMEDIUM GROUP» Ltd. |
| record_format | Article |
| series | Атеротромбоз |
| spelling | doaj.art-8a5c171b2665427d91b01e473d54f3822023-03-13T07:10:42Zrus«REMEDIUM GROUP» Ltd.Атеротромбоз2307-11092658-59522019-06-0101364310.21518/2307-1109-2019-1-36-43159RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUME. A. Shcheglov0N. N. Alontseva1P. S. Guliaeva2Федеральное государственное бюджетное образовательное учреждение высшего образования «Петрозаводский государственный университет» Государственное бюджетное учреждение здравоохранения Республики Карелия «Больница скорой медицинской помощи»Государственное бюджетное учреждение здравоохранения Республики Карелия «Больница скорой медицинской помощи»Федеральное государственное бюджетное образовательное учреждение высшего образования «Петрозаводский государственный университет»The aim of this study was to assess the risk of use of rivaroxaban, which was associated with gastro-duodenal bleeding in patients with deep venous thrombosis. Methods: an analysis of anticoagulant treatment in 683 patients with deep venous phlebothrombosis. All the patients underwent fiberoptic gastroduodenoscopic procedure prior to the anticoagulant treatment. When erosive-ulcerative lesions were detected, the patients received antisecretory therapy with proton pump inhibitors along with anticoagulant therapy. Results: EGD did not show any only stomach pathology only in 10.7 percent of patients at the time of admission. A symptom-free pathology that became a diagnostic finding was identified in 53.1 percent of patients. Fiberoptic gastroduodenoscopy showed completed bleeding or bleeding that was stopped using endoscopic balloon tamponade with achievement of stable hemostasis in 12.9 patients. 59.1 percent of patients received anti-coagulant therapy with rivaroxaban (Xarelto®). In the presented series of patients with acute deep vein thrombosis, the use of rivopoxaban appeared a safe therapeutic option not only in patients with erosive-ulcerative lesions in the gastroduodenal system, but also in those with endoscopic signs of stopped bleeding (on the top of already administered antisecretory therapy with proton pump inhibitors).https://www.aterotromboz.ru/jour/article/view/181острый тромбоз глубоких венривароксабанбезопасностьгастродуоденальные кровотеченияантисекреторная терапия |
| spellingShingle | E. A. Shcheglov N. N. Alontseva P. S. Guliaeva RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM Атеротромбоз острый тромбоз глубоких вен ривароксабан безопасность гастродуоденальные кровотечения антисекреторная терапия |
| title | RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM |
| title_full | RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM |
| title_fullStr | RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM |
| title_full_unstemmed | RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM |
| title_short | RIVAROXABAN SAFETY DURING DEEP VEIN THROMBOSIS TREATMENT IN PATIIENTS WITH RELATED DAMAGES OF STOMACH AND DUODENUM |
| title_sort | rivaroxaban safety during deep vein thrombosis treatment in patiients with related damages of stomach and duodenum |
| topic | острый тромбоз глубоких вен ривароксабан безопасность гастродуоденальные кровотечения антисекреторная терапия |
| url | https://www.aterotromboz.ru/jour/article/view/181 |
| work_keys_str_mv | AT eashcheglov rivaroxabansafetyduringdeepveinthrombosistreatmentinpatiientswithrelateddamagesofstomachandduodenum AT nnalontseva rivaroxabansafetyduringdeepveinthrombosistreatmentinpatiientswithrelateddamagesofstomachandduodenum AT psguliaeva rivaroxabansafetyduringdeepveinthrombosistreatmentinpatiientswithrelateddamagesofstomachandduodenum |